NewGenIVF Group Limited — FY2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023, compared with FY2022. This is an annual report, not a standalone Q4 filing. The audited statements relate to Legacy NewGenIvF Limited before the business combination, which closed April 3, 2024. Financial statements are prepared under U.S. GAAP.
Business context
The company provides assisted reproductive services through clinics in Thailand, Cambodia and Kyrgyzstan, with a Hong Kong marketing and administrative office. Its principal services are IVF treatment and surrogacy-related care. In 2023, IVF represented 78.3% of revenue, up from 47.4% in 2022; surrogacy and ancillary services represented 21.7%, down from 52.6%.
Financial performance and liquidity
| Metric (US$ unless stated) | FY2023 | FY2022 | Change / note |
|---|---|---|---|
| Revenue | 5.136 million | 5.944 million | Down 13.6% |
| Gross profit / margin | 1.682 million / 32.7% | 1.538 million / 25.9% | Gross profit up 9.4%; margin improved |
| Operating income / margin | 42,242 / 0.8% | 398,705 / 6.7% | Lower, with higher operating expenses |
| Net income / margin | 108,418 / 2.1% | 135,847 / 2.3% | Net income down about 20% |
| Net income attributable to company shareholders | 130,193 | 458,667 | Different from consolidated net income due to non-controlling interests |
| Net cash from operating activities | (1.766 million) | 1.711 million | Changed to substantial cash use |
| Net cash from investing activities | (69,848) | (94,452) | Primarily equipment purchases |
| Net cash from financing activities | 1.881 million | (1.634 million) | 2023 inflow primarily from related parties/shareholder funding |
| Cash and cash equivalents at year-end | 54,104 | 27,556 | Low absolute cash balance |
| Working capital | Surplus 79,000 | Deficit 157,027 | Improved, but current assets include material receivables and deferred IPO costs |
| Total liabilities | 1.241 million | 2.804 million | Lower, mainly as contract liabilities and related-party borrowing declined |
| Lease liabilities | 326,107 operating; 6,446 finance | 426,838 operating; 25,204 finance | Lease obligations remain |
IVF revenue rose 42.7% to US$4.022 million, attributed to expansion of Thailand IVF services. Surrogacy and ancillary-care revenue fell 64.3% to US$1.114 million, reflecting a temporary cessation/reduction in the business and the departure of an agent that had referred clients. Revenue originating in Kyrgyzstan fell to 60.8% of total from 85.1%; Thailand and Cambodia revenue increased.
Gross margin improved as management cited a revised subcontractor cooperation model and lower unit service costs. Cost of revenue declined 21.6% to US$3.454 million. Operating expenses rose 43.9% to US$1.640 million, including US$362,149 of audit fees and listing-related professional costs. Other income included an approximately US$88,151 waiver of a related-party balance. The company reported no income tax provision for 2023, compared with US$208,141 in 2022.
Material changes, outlook and risks
- Going concern and funding: The auditor highlighted substantial doubt about the company’s ability to continue as a going concern, citing year-end cash of US$54,104 and FY2023 operating cash outflow of US$1.766 million. Management stated that US$2 million of funding was received after year-end and that, by April 4, 2024, US$2 million had been provided to settle certain accounts payable. The filing gives no assurance that additional financing will be available on acceptable terms. The post-year-end funding included convertible notes; up to US$3.5 million was contemplated, and US$2 million had been issued by April 4, 2024.
- Debt and liquidity quality: Year-end balance-sheet liabilities included US$486,706 of taxes payable, while the contingencies note separately says a possible Kyrgyzstan late-tax-filing penalty of US$486,706 was reasonably possible, not provided for, and not estimable with certainty. The relationship between these disclosures is not clear from the filing text. Current assets also included US$354,285 due from shareholders and a US$140,000 loan to A SPAC I, in addition to US$373,677 of deferred IPO costs.
- Business and market risks: Results rely significantly on international patients, including Chinese clients, traveling to the company’s clinics. Travel disruption, economic weakness, safety perceptions, foreign exchange movements, competition and evolving fertility regulations could affect demand. The company also faces clinical liability, data privacy and cybersecurity, licensing, and supplier risks.
- Regulatory and property matters: The Thailand clinic had lease-title documentation and facility-registration issues disclosed by the company; potential outcomes include relocation and penalties. The Kyrgyzstan lease was not registered. The company also disclosed a possible Thailand penalty relating to previously provided accommodation without a tourism license, which it says ceased in early 2023.
- Insurance and legal exposure: The company stated it had no insurance coverage for its operations and no professional malpractice liability insurance for physicians and nurses. A prior specialist remuneration dispute was settled for approximately US$98,000. It reported no material legal proceedings as of the filing.
- Controls and accounting: Management concluded disclosure controls were ineffective and reported a material weakness involving insufficient staff with U.S. GAAP financial-reporting expertise. Planned remediation includes hiring accounting staff, training and formalizing period-end procedures; completion and effectiveness are not assured. Prior-year financial statements were restated for subscription-receivable classification and unrecorded directors’ remuneration.
- Outlook: Management plans to expand services and facilities, increase brand awareness, pursue partnerships or acquisitions, and open a second Thailand consultation clinic, expected in 2024. The filing provides no quantified financial guidance or forecast.
Most important facts for investors to verify
- Whether cash generation improved after FY2023 and whether the US$2 million post-year-end funding adequately covers operating needs; review the convertible-note terms, conversion features and any remaining availability.
- The actual status and potential payment exposure for the US$486,706 tax-payable/possible-penalty disclosure, including Kyrgyzstan filings and any provision or assessment.
- Whether the sharp decline in surrogacy revenue is temporary, and whether client referrals and international travel demand have recovered.
- Collectability and repayment of the US$354,285 due from shareholders, alongside the terms and settlement of the A SPAC I loan and deferred IPO costs.
- Remediation of the material weakness and any subsequent auditor or reporting developments; also assess potential dilution from post-combination securities and convertible financing.